Patients with myeloid malignancies and either the 3q21q26 syndrome or t(1;3)(p36;q21) have been reported to share similar clinicopathological features and a common molecular mechanism for leukemogenesis. Overexpression of MDS1/EVI1 (3q26) or MEL1/PRDM16 (1p36), both members of the PR-domain family, has been directly implicated in the malignant transformation of this subset of neoplasias. The breakpoints in both entities are outside the genes, and the 3q21 region, where RPN1 is located, seems to act as an enhancer. MEL1 has been reported to be expressed in leukemia cells with t(1;3) and in the normal uterus and fetal kidney, but neither in bone marrow (BM) nor in other tissues, suggesting that this gene is specific to t(1;3)-positive MDS/AML. We report the molecular characterization of a t(1;3)(p36;q21) in a patient with MDS (RAEB-2). In contrast to previous studies, we demonstrate that MEL1, the PR-containing form, and MEL1S, the PR-lacking form, are widely expressed in normal tissues, including BM. The clinicopathological features and the breakpoint on 1p36 are different from cases previously described, and MEL1 is not overexpressed, suggesting a heterogeneity in myeloid neoplasias with t(1;3).
The 3q21q26 syndrome is associated with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML), and is characterized by trilineage dysplasia, in particular dysmegakaryocytopoiesis, and poor prognosis (Secker-Walker et al., 1995) . A similar type of MDS/AML has been reported in the recurrent t(1;3)(p36;q21). Patients with both entities seem to share similar clinicopathological features and a common molecular mechanism. The leukemogenic mechanism in these aberrations has been suggested to be the ectopic expression of EVI1 in patients with inv(3)(q21q26) and t(3;3)(q21;q26), and of MEL1/PRDM16 in patients with t(1;3)(p36;q21) (Mochizuki et al., 2000) , in both cases for juxtaposition with regulatory sequences of the housekeeping gene RPN1. The breakpoints (BPs) are outside the genes in most cases, and the 3q21 region, where RPN1 is located, seems to act as an enhancer, activating the transcription of these genes. MDS1-EVI1 (3q26) and MEL1 (1p36) are members of the family of PR-domain genes along with RIZ1/PRDM2 (1p36), BLIMP-1/PRDM1 (6q21) and PFM1/PRDM4 (12q23) (Schneider et al., 2002) . The protein products of these genes are involved in human cancer in an unusual yinyang fashion. It seems that two products are normally produced from a PR-domain family member, which differ by the presence or absence of the PR domain; the PR-plus product is disrupted or underexpressed, whereas the PR-minus product is present or overexpressed in cancer cells. This imbalance in the amount of the two products, a result of either genetic or epigenetic events, appears to be an important cause of malignancy (Huang, 1999) .
MEL1 (1p36.3) encodes a zinc-finger protein that shares 63% sequence similarity to MDS1-EVI1, with a similar domain structure. Mochizuki et al. (2000) reported that MEL1 is expressed in leukemia cells with t(1;3) but not in normal bone marrow (BM), suggesting that the ectopic expression of MEL1 is specific to the t(1;3)-positive MDS/AML. Recently, the same group has identified two different MEL1 products of 170 and 150 kDa by immunoblotting analysis, designated as fulllength MEL1 and short-form MEL1S, respectively (Nishikata et al., 2003) . Like MDS1-EVI1 and EVI1, two mRNAs with and without the PR domain would be transcribed from this locus. MEL1 is the PR-containing form, with the PR domain coded from codon ATC91 (exon 2) to codon CCC223 (exon 5) (Mochizuki et al., 2000) , and MEL1S is the PR-lacking form initiated from an internal codon ATG599 (exon 9) (Nishikata et al., 2003) . The fusion of MEL1 or MEL1S to GAL4 DNA-binding domain made them GAL4-binding site-dependent transcriptional repressors. Moreover, overexpression of MEL1S blocked granulocytic differentiation induced by G-CSF in IL-3-dependent murine myeloid L-G3 cells, while MEL1 could not block the differentiation. From these results, they conclude that overexpression of MEL1S could be one of the causative factors in the pathogenesis of t(1;3)-positive myeloid leukemia cells (Nishikata et al., 2003) . Here, we report the molecular characterization of a translocation t(1;3)(p36;q21) in a patient with MDS (RAEB-2). The clinicopathological features and the BP on 1p36 are different from AML cases previously described, and MEL1 is not overexpressed in our patient, suggesting a heterogeneity in cases with t(1;3). We also report the pattern of expression of MEL1 and MEL1S, which we show is different from that previously described.
G banding and FISH analysis showed a single clone 46,XX,t(1;3)(p36;q21) in the karyotype of a patient with MDS ( Figure 1 ). This 75-year-old woman was admitted because of leukocytosis, anemia and thrombocytopenia in June 1998. On physical examination, remarked bilateral edema, multiple bruises and petechiae and pallor, without hepatosplenomegaly or gingival swelling, was observed. BM examination showed hyperplastic marrow with an increased level of myeloblasts with monocytoid differentiation (18.6%). Refractory anemia with excess of blasts (RAEB-2) was diagnosed in the presence of 16% blasts. Treatment with cytosinearabinoside, idarubicin and etoposide was started, but the patient died 6 months later of respiratory distress. Fifteen BAC and PACs located on 1p36.3 and nine on 3q21 were used in metaphase FISH experiments. The BP on chromosome 1 was located between RP11-181G12 and RP11-740P5 (Figure 2a ). RP3-395M20, located between the two BACs that defined the BP, was deleted. Therefore, we could define the BP on 1p36.3 located 300 kb telomeric to MEL1, and a cryptic deletion of less than 400 kb was detected (Figure 1b) . The molecular characterization of similar translocations was first described by Mochizuki et al. in four patients with AML-M4 (Mochizuki et al., 2000) ; the BP on 1p36 was located in a 90-kb cluster telomeric to MEL1. Recently, Xinh et al. (2003) defined the localization of the BPs on 1p36 in two of these cases, and in a new patient with t(1;3). In the two patients reported by Mochizuki et al. (2000) , the BP was in RP5-907A6 (BR-2), 78.4-kb telomeric to MEL1; in the new patient, who presented an unusual clinical profile, the BP was located in RP1-163G9 (BR-1), in the first intron of MEL1. Both BPs are centromeric to the BP we define in our patient with RAEB, that it is located 250 kb telomeric to ARPM2 and 300 kb telomeric to MEL1 (Figure 2a ). This suggests a heterogeneity in cases with t(1;3), which could reflect the clinical features. The diagnosis of our patient was RAEB, the subtype most frequent (42.8%) among cases with MDS and t(1;3), whereas Xinh et al. defined the BP in three patients with AML-M4, the most frequent FAB subtype (53.8%) among cases with AML and t(1;3) (Xinh et al., 2003) . The clinicopathological profile is also different in our patient, suggesting that not all cases sharing t(1;3) are similar to the 3q21q26 syndrome, and that a different molecular mechanism could be present in this patient. The BP in chromosome 3 was between RP11-525K18 and RP11-475N22 (Figure 2b ). Both probes showed a small signal on the der(3) and der(1), respectively, suggesting that part of these chromosome 3 probes is deleted. Probes located between 525K18 and 475N22 showed no signal neither on der(3) nor on der(1), confirming that a region of about 500 kb is deleted ( Figure 1c ). Although the 3q21 BPs in cases with t(1;3) have been reported to cluster specifically in a region of 50 kb (BCR-C), centromeric to the 30 kb BCR of 3q21q26 syndrome cases (BCR-T), both downstream of the RPN1 gene , a recent review revealed that in six cases with inv(3), four with t(3;3) and three with t(1;3), the BP was in BCR-C and in nine cases with inv(3), seven with t(3;3) and three with t(1;3) in BCR-T (Wieser, 2002) . Therefore, both BCR may be affected by these alterations. The BP in our patient with t(1;3) and RAEB was less than 100 kb centromeric to GR6 and RPN1, in the BCR-C region. 3
0 RACE experiments with primers in GR6 showed no new sequences (data not shown). This is the first time that both, 1p36 and 3q21 BPs, have been defined in a t(1;3)(p13;q21).
On the basis of the positional relationship between MDS1-EVI1 and MEL1, Mochizuki et al. (2000) suggested that both genes are transcriptionally activated by the translocation of the 3q21 region with RPN1. from chromosome 1 labels normal chromosome 1 and der(1). RP3-395M20 probe (red) from chromosome 1 labels only normal 1, indicating that this region is deleted in the der(1). (c) RP11-689D3 probe (red) and RP11-475N22 (green) from chromosome 3 label normal chromosome 3 and der(1). The small green signal on der(1) suggests that part of this chromosome 3 probe is deleted. DNA from BAC and PAC clones was extracted using Qiaprep s Spin Miniprep kit (Qiagen, Hilden, Germany), and labeled with Spectrum Green s and Spectrum Orange s (Vysis, Downers Grove, IL, USA) by nick translation. FISH analysis was performed on BM metaphases as previously described (Odero et et al. (2000) reported that MEL1 is expressed in the uterus, fetal kidney, and specifically in leukemia cells with t(1;3), but not in other cell lines or in normal BM, spleen, or fetal liver, suggesting that the ectopic expression of MEL1 is specific to the t(1;3)-positive MDS/AML (Mochizuki et al., 2000) . The MEL1 gene codes for two products that differ in the presence or absence of the PR domain. In order to distinguish the expression pattern of these two forms, we designed two sets of primers. We used primers MEL1N-F and MEL1N-R, located outside the PR-domain sequence, in a region conserved in all the splicing variants, to amplify the region common to MEL1 and MEL1S (cMEL). It is not possible to discriminate between these two products, since MEL1S is contained in the MEL1 sequence. Primers MEL1PR-F and MEL1PR-R were designed in exon 3 and exon 5, respectively, that code for the PR domain, to amplify only MEL1 (Figure 3a) . Primer sequences are shown in Table 1 . We analysed the expression pattern of MEL1 and cMEL (MEL1 plus MEL1S) by RT-PCR separately on CD34 þ cells, BM and peripheral blood (PB) of a healthy donor, normal uterus, and in BM of the patient. All reactions showed bands of 260 and 200 bp, as expected for MEL1 and cMEL amplifications, respectively, with the primers used (Figure 3a, b) . Sequence analysis of the RT-PCR products confirmed these results. We also amplified MEL1 and cMEL in a set of first-strand cDNAs from eight human tissues: heart, brain, placenta, lung, liver, skeletal muscle, kidney and pancreas. The expression was detected in all the tissues of the panel, being stronger in the heart, lung, kidney and pancreas (Figure 3b) . Therefore, MEL1 and MEL1S were expressed in at least 11 normal tissues, including BM and PB, and in the BM of the patient. The set of primers used for Mochizuki et al. (2000) did not discriminate between MEL1 and MEL1S; hence, their analysis really showed the expression of the region shared by both transcripts. The differences in these results could be explained because the RT-PCR conditions Mochizuki Figure 2 Integrate map of the 1pter-1p36.3 and 3q21 regions showing the ideograms of chromosomes 1 and 3 with the FISH results of a patient with t(1;3)(p36;q21). The physical map and relative size and position of genes involved in human cancer and of the clones used in this study (GenBank Accession number in brackets) are shown in the diagram. The clones were obtained from libraries from the Roswell Park Cancer Institute (Buffalo, NY, USA). (a) The BP on 1p36.3 in the patient with t(1;3) was located between RP11-181G12 and RP11-740P5. We found a cryptic deletion of less than 400 kb. BR-1 and BR-2: BPs of three patients with t(1;3) and AML-M4, described by Xinh et al. (2003) . (b) The BP in chromosome 3 was between RP11-525K18 and RP11-475N22
Characterization of a new t(1;3) and MEL1 expression pattern I Lahortiga et al et al. used are more restrictive (30 versus 35 cycles), although in their experiments both Northern and RT-PCR showed the same results. However, our experiments showed a strong expression of MEL1 and cMEL in the heart, lung, kidney and pancreas, which should have been easily detected by Mochizuki et al. (Figure 3b ). Interestingly, a recent report showed the same profile expression in the analysis of MDS1/EVI1 (PR positive) versus cEVI1, a region common to MDS1/ EVI1 and EVI1 (PR negative type), using a similar experimental design (Vinatzer et al., 2003) . The expression of both genes was stronger in the same tissues, with the only exception of placenta, where MDS1-EVI1 and cEVI1 are highly expressed, whereas MEL1 and cMEL are poorly expressed. Fractionated CD34 þ progenitor cell populations indeed showed high MEL1 and MEL1S expression. Previous studies also confirmed MDS1-EVI1 and EVI1 expression in early CD34 þ progenitor cells, and suggest that transformation in these progenitors may be the result of a disturbance in the tightly controlled balance between EVI1 and its fusion transcript (Barjesteh van Waalwijk van Doorn-Khosrovani et al., 2003) . We designed a semiquantitative RT-PCR experiment to compare the expression of cMEL in the BM of the patient and that of a healthy donor, using (b) Expression of MEL1 (I) and expression of cMEL (II) was performed on cDNA from BM and PB of a healthy donor, normal uterus, and on a set of normalized, first-strand cDNA from eight different human tissues (Multiple Tissue cDNA Panels I; Clontech, Basingstoke, UK). (c) Multiplex-PCR to amplify MEL1 and cMEL in the same reaction was performed to avoid differences in the amplification level derived from external causes such as variability of the PCR technique, using a mix of MEL1PR-F, MEL1PR-R, MEL1N-F and MEL1N-R primers. Multiplex-PCR was performed in BM of a healthy donor (N) and BM of the patient with t(1;3) (P). Aliquots of both reactions were taken from cycles 33-41, at the moment of the denaturation step, in order to ensure that amplifications were in the linear phase of amplification. Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Hilden, Germany) from frozen cell pellets of BM and PB from a healthy donor, uterus and leukemic cells. The CD34 þ cells isolation was performed from mononuclear cells of normal BM, using the Direct CD34 Progenitor cell isolation kit (Miltenyi Biotec, Germany). Total RNA (1 mg) was used for cDNA synthesis using SuperScriptt II RNase H-RT (Invitrogen Life Technologies, Paisley, UK) with random hexamers. RT-PCR reactions were performed under standard conditions using AmpliTaq Gold s DNA Polymerase (Applied Biosystems, Foster City, CA, USA), annealing temperature 651C and 35 cycles. PCR products were subcloned using the TOPO TA Cloning Characterization of a new t(1;3) and MEL1 expression pattern I Lahortiga et al primers MEL1N-F and MEL1N-R. Amplification of BCR was used as an internal control. The expression pattern of cMEL in a normal BM in comparison with BM of the patient was 1/1.28, indicating that this gene is not overexpressed in our patient with t(1;3). In order to better discriminate between MEL1 and MEL1S, we designed a multiplex RT-PCR experiment. In normal BM, expression of cMEL (MEL1 plus MEL1S) was stronger than the expression of only MEL1, which accounted for around half of the total expression. In the patient sample, both amplifications had the same intensity, suggesting that MEL1S could be underexpressed (Figure 3c ). The overexpression of zinc-finger proteins lacking the PR domain is considered one of the main factors in the pathogenesis of some leukemias, being present or overexpressed in many tumors (Huang, 1999 (Huang, , 2002 . The yin-yang mechanism, well studied in the RIZ gene, was expected to be repeated in other PR family members. Gene silencing of RIZ1, but not RIZ2, is common in many types of tumors, and is associated with promoter DNA methylation; therefore, the PR domain has been associated with the tumor-suppressor properties of RIZ1 (Du et al., 2001; Huang, 2002) . Surprisingly, the form without PR (MEL1S) seems to be poorly expressed in our patient. However, a review of the literature shows that not all members of the PRdomain family work in the same way. Two recent studies detected in 17/21 (81%) patients with t(3;3) or inv(3) that high EVI1 expression was associated with high MDS1-EVI1 expression, the form with the PR domain (Barjesteh van Waalwijk van Doorn- Khosrovani et al., 2003; Vinatzer et al., 2003) . Moreover, lack of expression of the PR-lacking form EVI1 has been reported in several cases with syndrome 3q21q26 (Fichelson et al., 1992; Morishita et al., 1992; Soderholm et al., 1997; Langabeer et al., 2001) , suggesting that the molecular mechanism of leukemogenesis is not the same in all patients. Barjesteh van Waalwijk van DoornKhosrovani et al. rearrangements. In a patient with RAEB and t(3;12)(q26;p13), the relative expression of EVI1 when compared with MDS1-EVI1 was 1/11585. This translocation t(3;12) is different from the classical t(3;3) or inv(3), although EVI1 (3q26) is also involved. In the leukemic cells of the case presented here, with MDS and a t(1;3), MEL1 is expressed and MEL1S, the PRdomain negative form, seems to be underexpressed. These data would confirm the results of previous reports about MDS1-EVI1, and could indicate that different molecular mechanisms are possible for the members of the family of PR-domain genes. On the other hand, data reported by Pekarsky et al. (1997) and Rynditch et al. (1997) suggest that the 3q21 region is gene rich, and additional genes instead of RPN1 could be involved in these rearrangements. GATA-2, located in RP11-475N22, had been reported as a candidate gene involved in the 3q21 BP (Wieser, 2002) . However, the location of the BP in our patient suggests that this gene is deleted.
We have analysed the expression of GATA-2 in the patient BM, and the level of expression was similar when comparing with normal BM and PB (data not shown).
In conclusion, the data presented here showed that MEL1 and MEL1S are widely expressed in tissues, including PB and BM. We report the molecular characterization of a novel t(1;3)(p36;q21) in a patient with MDS (RAEB-2). The clinicopathological features and the BP on 1p36 are different from cases previously described, and MEL1 was not overexpressed; instead, imbalance of a complete MEL1 message with a PR domain and a short MEL1 message lacking a PR domain (MEL1S) might be involved in the leukemogenesis of this patient. These observations suggest a heterogeneity in myeloid neoplasias with t(1;3), as has been reported for cases with 3q21q26 syndrome.
